Year: 2017
BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma
May 22, 2017
Bergen, Norway, May 22 8am (CET) – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company…
Read MoreBerGenBio ASA: First Quarter 2017 Results Presentation and Webcast
May 18, 2017
Bergen, Norway, 16 May 2017: BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl…
Read MoreBerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer
March 8, 2017
Bergen, Norway, 8 March 2017: BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl…
Read MoreBerGenBio To Present At 9th Annual Biotech Showcase 2017
January 10, 2017
Bergen, Norway, January 4, 2016 – BerGenBio AS, a clinical stage biopharmaceutical company focused on…
Read MoreBerGenBio is considered an inspirational example by Norway’s PM Erna Solberg during her New Year address to the nation
January 3, 2017
Bergen, Norway, January 2, 2017 – Leading oncology biopharmaceutical company BerGenBio AS, today announced that…
Read More
